NuProbe
Biotechnology ResearchTexas, United States11-50 Employees
NuProbe prototypes and validates high-sensitivity genomics panels for difficult DNA biomarkers including CNVs, gene fusions, and low-frequency mutations.
Strategic Partnerships NuProbe has successfully entered exclusive licensing agreements with Bio-Rad Laboratories for allele enrichment technologies, presenting an opportunity to leverage this partnership for further sales collaborations and market expansion.
Investment Backing Securing significant investments from prominent firms like Pappas Capital, Chinainvestorsclub, and Panlincap, NuProbe's financial health signals confidence in its growth trajectory, making it an attractive prospect for potential sales partnerships or investments.
Market Expansion NuProbe's recent developments in highly multiplexed digital PCR assays have drawn attention from companies like Signum Health Ltd, offering avenues for exploring collaborative sales opportunities to enhance oncology offerings and penetrate new markets.
High Funding Acquisition Closing a substantial Series B funding round of $50 million indicates NuProbe's robust financing capability, positioning the company to pursue innovative product development and potentially seek new sales channels and collaborations.
Advanced Technology With a tech stack encompassing diverse tools such as Smartlook, Google Ads Conversion Tracking, and GitHub, NuProbe showcases a commitment to cutting-edge technology adoption that can be leveraged to attract tech-savvy customers and drive sales growth through technological advantages.
NuProbe uses 8 technology products and services including Smartlook, Google Ads Conversion Tracking, GitHub, and more. Explore NuProbe's tech stack below.
NuProbe Email Formats | Percentage |
First.Last@nuprobe.com | 66% |
FirstLast@nuprobe.com | 27% |
FirstLas@nuprobe.com | 4% |
FLast@nuprobe.com | 3% |
Biotechnology ResearchTexas, United States11-50 Employees
NuProbe prototypes and validates high-sensitivity genomics panels for difficult DNA biomarkers including CNVs, gene fusions, and low-frequency mutations.
NuProbe has raised a total of $50M of funding over 4 rounds. Their latest funding round was raised on Jun 02, 2022 in the amount of $50M.
NuProbe's revenue is in the range of $10M
NuProbe has raised a total of $50M of funding over 4 rounds. Their latest funding round was raised on Jun 02, 2022 in the amount of $50M.
NuProbe's revenue is in the range of $10M